Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a non-steroidal anti-inflammatory (NSAID), selective inhibitor of cyclooxygenase-2 (COX-2) that is used in the treatment of rheumatoid arthritis and other rheumatic diseases. Topical or oral administration once daily.
It is excreted in breast milk in clinically non-significant amount and no problems have been observed in infants whose mothers took this medication. (Ostensen 1988 y 1983)
Levels in plasma and urine of such infants were undetectable. (Ostensen 1988 y 1983)
Having published less quantity of studies than with other NSAIDs, safer alternatives may be preferable, especially in the neonatal period and in case of prematurity.
Expert authors consider the use of meloxicam to be probably safe during breastfeeding (Hale, Briggs 2015, Østensen 2007, Janssen 2000). The American Academy of Pediatrics rates it as usually compatible with breastfeeding. (AAP 2001)